Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients


Study Number
659920
Phase
1/2a
Age Group
Adult
Purpose

This phase I/IIa trial studies the best dose and side effects of rintatolimod and interferon (IFN) alpha-2b in treating cancer patients with COVID-19 infection. Interferon alpha is a protein important for defense against viruses. It activates immune responses that help to clear viral infection. Rintatolimod is double stranded ribonucleic acid (RNA) designed to mimic viral infection by stimulating immune pathways that are normally activated during viral infection. Giving rintatolimod and interferon alpha-2b may activate the immune system to limit the replication and spread of the virus.

Full Title

Phase 1/2A Study of Rintatolimod and IFN alpha Regimen in Cancer Patients with Mild or Moderate COVID-19 Infection

ClinicalTrials.Gov ID
NCT04379518

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.